New Injectable Agents for the Treatment of Type 2 Diabetes Part 2—Glucagon-Like Peptide-1 (GLP-1) Agonists

Christa George, Ah Young Byun, Amanda Howard-Thompson

Research output: Contribution to journalReview article

Abstract

The US Food and Drug Administration has recently approved several new glucagon-like peptide-1 (GLP-1) agonists alone and in combination with various insulin products. The second of 2 articles in a series, this review will describe the potential advantages and disadvantages of the GLP-1 agonist class of products.

Original languageEnglish (US)
Pages (from-to)1304-1306
Number of pages3
JournalAmerican Journal of Medicine
Volume131
Issue number11
DOIs
StatePublished - Nov 1 2018

Fingerprint

Glucagon-Like Peptide 1
Type 2 Diabetes Mellitus
Peptides
Injections
United States Food and Drug Administration
Insulin
Therapeutics

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Cite this

New Injectable Agents for the Treatment of Type 2 Diabetes Part 2—Glucagon-Like Peptide-1 (GLP-1) Agonists. / George, Christa; Byun, Ah Young; Howard-Thompson, Amanda.

In: American Journal of Medicine, Vol. 131, No. 11, 01.11.2018, p. 1304-1306.

Research output: Contribution to journalReview article

@article{7d76f3a41b9e4e2185fd3b25c0263262,
title = "New Injectable Agents for the Treatment of Type 2 Diabetes Part 2—Glucagon-Like Peptide-1 (GLP-1) Agonists",
abstract = "The US Food and Drug Administration has recently approved several new glucagon-like peptide-1 (GLP-1) agonists alone and in combination with various insulin products. The second of 2 articles in a series, this review will describe the potential advantages and disadvantages of the GLP-1 agonist class of products.",
author = "Christa George and Byun, {Ah Young} and Amanda Howard-Thompson",
year = "2018",
month = "11",
day = "1",
doi = "10.1016/j.amjmed.2018.05.043",
language = "English (US)",
volume = "131",
pages = "1304--1306",
journal = "American Journal of Medicine",
issn = "0002-9343",
publisher = "Elsevier Inc.",
number = "11",

}

TY - JOUR

T1 - New Injectable Agents for the Treatment of Type 2 Diabetes Part 2—Glucagon-Like Peptide-1 (GLP-1) Agonists

AU - George, Christa

AU - Byun, Ah Young

AU - Howard-Thompson, Amanda

PY - 2018/11/1

Y1 - 2018/11/1

N2 - The US Food and Drug Administration has recently approved several new glucagon-like peptide-1 (GLP-1) agonists alone and in combination with various insulin products. The second of 2 articles in a series, this review will describe the potential advantages and disadvantages of the GLP-1 agonist class of products.

AB - The US Food and Drug Administration has recently approved several new glucagon-like peptide-1 (GLP-1) agonists alone and in combination with various insulin products. The second of 2 articles in a series, this review will describe the potential advantages and disadvantages of the GLP-1 agonist class of products.

UR - http://www.scopus.com/inward/record.url?scp=85051025482&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85051025482&partnerID=8YFLogxK

U2 - 10.1016/j.amjmed.2018.05.043

DO - 10.1016/j.amjmed.2018.05.043

M3 - Review article

VL - 131

SP - 1304

EP - 1306

JO - American Journal of Medicine

JF - American Journal of Medicine

SN - 0002-9343

IS - 11

ER -